Before the market open, the company said it had positive interim data from the Phase 1 dose escalation part of the Phase 1/2 trial of SNDX-5613 in patients with genetically defined acute leukemias . The data showed 48% overall response rate in patients with mixed lineage leukemia rearranged or nucleophosmin mutant relapsed/refractory acute leukemias and 67% of responders achieved minimal residual disease-negative status. The company said it identified the doses for advancement into Phase 2 and is on track to initiate the pivotal Phase 2 portion of trial in the second quarter of 2021.
可是世道叵测,股价爆量暴跌30%。
我查到的是, 昨天大股东 AVIDITY PARTNERS MANAGEMENT 趁机购入了1.44 M shares, and reach 9.85% ownership。